Kumari Suchitra, Panda Tarun Kumar, Pradhan Tapaswini
Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
SCB Medical College and Hospital, Cuttack, India.
Indian J Clin Biochem. 2017 Jun;32(2):134-141. doi: 10.1007/s12291-016-0576-7. Epub 2016 May 11.
The mechanical properties of extracellular matrix (ECM) and connective tissues is largely dependent on the collagen and elastin structure. Lysyl oxidase (LOX) plays a critical role in the formation and repair of the ECM by oxidizing lysine residues in elastin and collagen, thereby initiating the formation of covalent cross linkages which stabilize these fibrous proteins. Due to its multiple functions both extracellularly and intracellularly, lysyl oxidase is involved in several processes in the tumorigenic pathway, in many different cancer types and stages. Alteration in LOX activity is implicated in many diseases and disorders including inflammation and inflammatory diseases, fibrosis of distinct organs and fibrotic disorders, cancer promotion and progression. There are only sparse reports of mutations or epigenetic alterations in the LOX gene. This review provides the recent clinical developments in the molecular mechanisms and pathologic process, pointing out LOX as a potential therapeutic target in translational medicine.
细胞外基质(ECM)和结缔组织的力学性能在很大程度上取决于胶原蛋白和弹性蛋白的结构。赖氨酰氧化酶(LOX)通过氧化弹性蛋白和胶原蛋白中的赖氨酸残基,在ECM的形成和修复中起关键作用,从而启动共价交联的形成,使这些纤维蛋白稳定。由于其在细胞外和细胞内的多种功能,赖氨酰氧化酶参与了多种不同癌症类型和阶段的肿瘤发生途径中的多个过程。LOX活性的改变与许多疾病和病症有关,包括炎症和炎症性疾病、不同器官的纤维化和纤维化病症、癌症的促进和进展。关于LOX基因的突变或表观遗传改变的报道很少。本综述提供了分子机制和病理过程方面的最新临床进展,指出LOX作为转化医学中的潜在治疗靶点。